Dr. Jennifer Chuy, MD
NPI: 1174826531
Total Payments
$14,999
2024 Payments
$116.20
Companies
25
Transactions
78
Medicare Patients
725
Medicare Billing
$170,308
Payment Breakdown by Category
Research$11,968 (79.8%)
Food & Beverage$1,561 (10.4%)
Consulting$1,250 (8.3%)
Education$219.71 (1.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,968 | 4 | 79.8% |
| Food and Beverage | $1,561 | 70 | 10.4% |
| Consulting Fee | $1,250 | 1 | 8.3% |
| Education | $219.71 | 3 | 1.5% |
Payments by Type
Research
$11,968
4 transactions
General
$3,031
74 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $13,316 | 5 | $0 (2019) |
| Amgen Inc. | $366.05 | 13 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $235.22 | 6 | $0 (2019) |
| AbbVie, Inc. | $113.03 | 5 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $110.84 | 3 | $0 (2018) |
| Ipsen Biopharmaceuticals, Inc | $101.44 | 3 | $0 (2018) |
| Astellas Pharma US Inc | $99.95 | 1 | $0 (2024) |
| Genentech USA, Inc. | $93.38 | 5 | $0 (2018) |
| Daiichi Sankyo Inc. | $85.60 | 5 | $0 (2018) |
| Taiho Oncology, Inc. | $68.59 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116.20 | 2 | Astellas Pharma US Inc ($99.95) |
| 2023 | $42.93 | 2 | Seagen Inc. ($23.12) |
| 2019 | $2,330 | 2 | Celgene Corporation ($2,310) |
| 2018 | $5,876 | 46 | Celgene Corporation ($4,767) |
| 2017 | $6,633 | 26 | Celgene Corporation ($6,240) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 2 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2018 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Oncology | ||||||
| 05/30/2018 | Amgen Inc. | Neulasta (Biological), NEUPOGEN | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Oncology | ||||||
| 05/30/2018 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Anemia | ||||||
| 05/28/2018 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: Oncology | ||||||
| 05/17/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Oncology | ||||||
| 05/08/2018 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: BioOncology | ||||||
| 05/04/2018 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Oncology | ||||||
| 05/03/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Oncology | ||||||
| 05/02/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: HEMATOLOGY | ||||||
| 04/27/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Oncology | ||||||
| 04/24/2018 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $11.10 | General |
| Category: Oncology | ||||||
| 04/20/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Virology | ||||||
| 04/18/2018 | PFIZER INC. | XALKORI (Drug), IBRANCE | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: ONCOLOGY | ||||||
| 04/03/2018 | Ipsen Biopharmaceuticals, Inc | Somatuline Depot (Drug), Onivyde | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 03/29/2018 | Amgen Inc. | — | Education | In-kind items and services | $99.95 | General |
| 03/28/2018 | Kyowa Kirin, Inc. | SANCUSO (Drug), IXEMPRA, FARESTON | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 03/16/2018 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Oncology | ||||||
| 03/15/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $72.38 | General |
| Category: Oncology | ||||||
| 03/14/2018 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2018 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: BioOncology | ||||||
| 02/28/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.45 | General |
| Category: Oncology | ||||||
| 02/20/2018 | Amgen Inc. | Aranesp (Biological), XGEVA | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Nephrology | ||||||
| 02/16/2018 | Ipsen Biopharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $60.42 | General |
| 02/14/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: HEMATOLOGY | ||||||
| 01/26/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-PANC-007 | Celgene Corporation | $4,867 | 1 |
| ABI-007-PANC-007 - nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). | Celgene Corporation | $4,767 | 1 |
| nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). (ABI-007-PANC-007) | Celgene Corporation | $2,310 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 143 | 438 | $251,114 | $38,579 |
| 2022 | 4 | 116 | 277 | $166,415 | $26,756 |
| 2021 | 7 | 202 | 567 | $327,080 | $60,214 |
| 2020 | 8 | 264 | 542 | $218,524 | $44,759 |
Total Patients
725
Total Services
1,824
Medicare Billing
$170,308
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 304 | $167,200 | $26,063 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $33,015 | $4,978 | 15.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 78 | $29,250 | $4,512 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 13 | $9,685 | $1,561 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $11,964 | $1,466 | 12.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 184 | $101,200 | $16,168 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $39,405 | $6,198 | 15.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 43 | $16,125 | $2,663 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 13 | $9,685 | $1,728 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 247 | $131,625 | $23,981 | 18.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 25 | 136 | $107,440 | $21,760 | 20.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 30 | $21,440 | $4,452 | 20.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 60 | $25,400 | $4,108 | 16.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 47 | $24,040 | $3,176 | 13.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 16 | 25 | $10,425 | $1,772 | 17.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 15 | 22 | $6,710 | $964.63 | 14.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 164 | $77,595 | $13,885 | 17.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 15 | 79 | $17,060 | $12,468 | 73.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 60 | 92 | $36,350 | $5,077 | 14.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 69 | $31,050 | $4,573 | 14.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $12,200 | $2,208 | 18.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 23 | 32 | $7,810 | $1,924 | 24.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 32 | $14,240 | $1,902 | 13.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 13 | $12,654 | $1,368 | 10.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 22 | 29 | $4,665 | $842.70 | 18.1% |
About Dr. Jennifer Chuy, MD
Dr. Jennifer Chuy, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2010. The National Provider Identifier (NPI) number assigned to this provider is 1174826531.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Chuy, MD has received a total of $14,999 in payments from pharmaceutical and medical device companies, with $116.20 received in 2024. These payments were reported across 78 transactions from 25 companies. The most common payment nature is "" ($11,968).
As a Medicare-enrolled provider, Chuy has provided services to 725 Medicare beneficiaries, totaling 1,824 services with total Medicare billing of $170,308. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Bronx, NY
- Active Since 12/07/2010
- Last Updated 06/02/2017
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174826531
Products in Payments
- Abraxane (Drug) $13,316
- NINLARO (Drug) $123.56
- SANDOSTATIN LAR (Drug) $120.80
- XGEVA (Biological) $103.26
- JADENU (Drug) $94.24
- Avastin (Biological) $93.38
- Neulasta (Biological) $93.18
- INJECTAFER (Drug) $85.60
- Lonsurf (Drug) $68.59
- Creon (Drug) $66.17
- OPDIVO (Biological) $58.52
- Venclexta (Drug) $46.86
- Kyprolis (Biological) $35.78
- Lenvima (Drug) $34.01
- Aranesp (Biological) $33.88
- FIRMAGON (Drug) $31.96
- KEYTRUDA (Biological) $31.65
- Folotyn (Drug) $27.79
- XALKORI (Drug) $25.75
- JEVTANA (Drug) $24.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Bronx
Dr. David Altschul, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $394,687
Student in an Organized Health Care Education/Training Program $394,687
Edvard Skripochnik, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $127,559
Student in an Organized Health Care Education/Training Program $127,559
Dr. Cynthia Armand
Student in an Organized Health Care Education/Training Program — Payments: $68,024
Student in an Organized Health Care Education/Training Program $68,024
Dr. Eric Woods, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,336
Student in an Organized Health Care Education/Training Program $40,336
Ms. Kavita Gupta, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $31,772
Student in an Organized Health Care Education/Training Program $31,772
Dr. Dmitriy Nevelev, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $30,107
Student in an Organized Health Care Education/Training Program $30,107